Iksuda Therapeutics Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary

Iksuda Therapeutics Ltd (Iksuda), formerly Glythera Ltd is a biotechnology company that focuses on the development of antibody drug conjugates (ADCs) and biotherapeutics for the treatment of cancer. The company develops antibody-based therapies for the treatment of cancer and broader based therapeutics. It uses its proprietary linker and stable glycan technologies permalink and premacarb to deliver solutions for development and manufacture efficacious and safe biologics to improve half-life and optimize bio-availability. The company partners with various biotech companies for its technology development activities. Iksuda is headquartered in Newcastle upon Tyne, the UK.

Iksuda Therapeutics Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

It derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.


List of Tables 4
List of Figures 4
Iksuda Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Iksuda Therapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Iksuda Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Iksuda Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Iksuda Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Iksuda Therapeutics Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Glythera Raises US$2 Million In Venture Financing 10
Partnerships 11
Avacta Enters into Agreement with Glythera 11
Licensing Agreements 12
Avacta Enters into Licensing Agreement with Glythera 12
Glythera Enters into Licensing Agreement with Cancer Research UK 13
Glythera Enters into Licensing Agreement with IONTAS 14
Iksuda Therapeutics Ltd - Key Competitors 15
Iksuda Therapeutics Ltd - Key Employees 16
Iksuda Therapeutics Ltd - Locations And Subsidiaries 17
Head Office 17
Recent Developments 18
Corporate Communications 18
Apr 30, 2018: Glythera Names Professor Kerry Chester to Scientific Advisory Board 18
Jan 17, 2018: Glythera Appoints Chief Scientific Officer and Strengthens SAB 19
Jul 31, 2017: Glythera Appoints Dr Mike Owen as Non-executive Director 20
Jul 31, 2017: Glythera appoints new non-executive director 21
Government and Public Interest 22
Jun 06, 2017: Glythera Launches UK government funded project to develop safer and more efficacious ADCs for the treatment of difficult-to-treat tumours 22
Product News 23
Feb 21, 2017: Glythera: Demonstrates improved activity and safety of PermaLink-based ADCs 23
Other Significant Developments 24
Sep 10, 2018: Glythera announces corporate name change and rebranding to Iksuda Therapeutics 24
Appendix 25
Methodology 25
About GlobalData 25
Contact Us 25
Disclaimer 25

List Of Tables


Iksuda Therapeutics Ltd, Pharmaceuticals & Healthcare, Key Facts 2
Iksuda Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Iksuda Therapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Iksuda Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Iksuda Therapeutics Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Iksuda Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Glythera Raises US$2 Million In Venture Financing 10
Avacta Enters into Agreement with Glythera 11
Avacta Enters into Licensing Agreement with Glythera 12
Glythera Enters into Licensing Agreement with Cancer Research UK 13
Glythera Enters into Licensing Agreement with IONTAS 14
Iksuda Therapeutics Ltd, Key Competitors 15
Iksuda Therapeutics Ltd, Key Employees 16

List Of Figures


Xinjiang Goldwind Science & Technology Co Ltd, Performance Chart (2013 - 2017) 31
Xinjiang Goldwind Science & Technology Co Ltd, Ratio Charts 33
Xinjiang Goldwind Science & Technology Co Ltd, Power, Deals By Year, 2012 to YTD 2018 34
Xinjiang Goldwind Science & Technology Co Ltd, Power, Deals by Type, 2012 to YTD 2018 35

Iksuda Therapeutics Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Iksuda Therapeutics Ltd (Iksuda), formerly Glythera Ltd is a biotechnology company that focuses on the development of antibody drug conjugates (ADCs) and biotherapeutics for the treatment of cancer. The company

USD 250 View Report

Kazia Therapeutics Ltd (KZA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Kazia Therapeutics Limited (Kazia Therapeutics), is a clinical stage biotechnology company which focuses on the discovery and development of anti-cancer drugs. It develops its products based on three drug technology

USD 250 View Report

Arcturus Therapeutics Ltd (ARCT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Arcturus Therapeutics Ltd (Arcturus), formerly Alcobra Ltd is a pharmaceutical company that develops a portfolio of nucleic acid therapeutics for treatment of diseases with unmet medical needs. It discovers and

USD 250 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available